Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
The cornerstone of lupus management is modulating the overactive immune system to prevent tissue damage while minimizing treatment toxicity. The therapeutic strategy is stratified based on the severity of organ involvement. For mild disease involving the skin and joints, the primary goals are symptom control and quality of life. For severe disease affecting the kidneys or the central nervous system, the goal shifts to organ preservation and preventing irreversible failure.
Antimalarial agents, specifically Hydroxychloroquine, are the foundational treatment for nearly all lupus patients. Initially used for malaria, this drug stabilizes lysosomes and inhibits the activation of toll-like receptors, reducing the processing of autoantigens. It is unique in its ability to prevent flares, reduce cardiovascular risk, and improve long-term survival with a relatively safe profile. It is considered a background therapy that continues even when other drugs are added.
Glucocorticoids, such as prednisone, are the most potent anti-inflammatory drugs available for the rapid control of active lupus. They work by suppressing the expression of inflammatory genes and inducing the apoptosis of immune cells. In acute flares, particularly those involving major organs, high-dose intravenous pulse steroids are often used to halt damage immediately.
However, the long-term use of corticosteroids is associated with significant toxicity, including weight gain, diabetes, osteoporosis, cataracts, and increased infection risk. Modern management protocols emphasize the concept of steroid-sparing strategies. The objective is to use the lowest effective dose for the shortest possible time, transitioning quickly to maintenance immunosuppressants to control the disease, allowing steroids to be tapered or discontinued.
To maintain remission and reduce reliance on steroids, immunosuppressive agents are used. Methotrexate and Azathioprine are commonly used for moderate disease affecting joints and skin. They work by inhibiting the proliferation of rapidly dividing immune cells. For severe organ-threatening disease, particularly lupus nephritis, Mycophenolate Mofetil and Cyclophosphamide are the standard of care. Mycophenolate inhibits B-cell and T-cell proliferation, while Cyclophosphamide is a potent alkylating agent that depletes immune cells.
The advent of biologic therapies has introduced targeted precision to lupus treatment. Belimumab is a monoclonal antibody that targets B-lymphocyte stimulator (BLyS), a protein essential for B-cell survival. By inhibiting BLyS, Belimumab reduces the number of autoreactive B-cells and has been shown to reduce disease activity and flares. Rituximab, another biologic used off-label in refractory cases, depletes CD20-positive B-cells entirely. These targeted therapies represent a shift away from broad immunosuppression towards dissecting specific pathogenic pathways.
Regenerative medicine offers a paradigm shift for patients with refractory lupus who do not respond to conventional therapies. Hematopoietic Stem Cell Transplantation (HSCT) is being investigated as a means to “reset” the immune system. This procedure involves harvesting the patient’s own stem cells, using high-dose chemotherapy to ablate the dysfunctional immune system (immunoablation), and then reinfusing the stem cells to reconstitute a new, naive immune system. The theory is that the new immune cells will undergo proper tolerance education, eliminating the autoimmune memory. While risky, this procedure has induced drug-free remission in patients with severe, life-threatening disease.
Mesenchymal Stem Cell (MSC) therapy is another promising avenue. Unlike HSCT, which obliterates the immune system, MSCs modulate the immune system. MSCs can be sourced from bone marrow, adipose tissue, or umbilical cord tissue. When infused, they exert potent anti-inflammatory effects, inhibiting T-cell proliferation and promoting the expansion of regulatory T cells (Tregs). This “soft reset” aims to restore the balance of the immune environment without the toxicity of chemotherapy. Clinical trials are ongoing to determine the optimal dosing and cell source for treating lupus nephritis and systemic flares.
Treatment extends beyond suppressing the immune system to managing the consequences of the disease. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are standard for patients with proteinuria to protect the kidneys and control blood pressure. Statins are frequently prescribed to manage the accelerated atherosclerosis associated with chronic inflammation. Anticoagulation therapy (warfarin or direct oral anticoagulants) is lifelong for patients with Antiphospholipid Syndrome who have experienced clots.
Bone health is aggressively managed with calcium, Vitamin D, and bisphosphonates to counteract the effects of chronic steroid use. Pain management involves a multimodal approach, avoiding opioids where possible, and utilizing physical therapy to maintain joint mobility and muscle strength.
Modern rheumatology has adopted the “treat-to-target” approach for lupus. This involves defining a specific goal, either remission or low disease activity, and adjusting therapy strictly until that goal is met. This proactive strategy contrasts with the older reactive approach of treating only when symptoms worsen. It relies on regular monitoring of disease activity indices and patient-reported outcomes to ensure that sub-clinical inflammation is not continuing to cause silent organ damage.
Send us all your questions or requests, and our expert team will assist you.
Hydroxychloroquine is the foundational medication for lupus. It modulates the immune system without causing severe immunosuppression. It reduces the frequency of flares, protects against organ damage, lowers the risk of blood clots, and improves long-term survival. It is typically prescribed to all lupus patients unless there is a specific contraindication.
While steroids are excellent at stopping inflammation quickly, their long-term use causes severe side effects, including bone loss, diabetes, weight gain, high blood pressure, and skin thinning. The goal is to use other medications to control the disease so that steroids can be reduced or stopped to prevent these long-term damages.
Traditional immunosuppressants broadly suppress the entire immune system. Belimumab is a biologic drug that specifically targets a protein called BLyS, which promotes B-cell survival. By targeting only this specific protein, it reduces the survival of the B-cells that produce autoantibodies, offering a more targeted approach with potentially fewer broad side effects.
The goal of Hematopoietic Stem Cell Transplantation (HSCT) is to delete the malfunctioning immune system and reboot it. By using chemotherapy to wipe out the immune cells that have “memory” of attacking the body, and then regenerating the system with stem cells, the hope is that the new immune system will be tolerant of the body’s own tissues.
Active inflammation in lupus nephritis is reversible with timely and aggressive treatment. However, if the inflammation persists, it leads to scarring (fibrosis) of the kidney tissue. Scar tissue is permanent and cannot be reversed. This is why early detection and treatment are critical to preserve kidney function before scarring occurs.
Your Comparison List (you must select at least 2 packages)
